...
【24h】

Glycocalyx protection reduces leukocyte adhesion after ischemia/reperfusion.

机译:Glycocalyx保护减少白细胞粘附缺血/再灌注后。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Adhesion of polymorphonuclear neutrophils (PMN) to coronary endothelium is a key event for cardiac ischemia/reperfusion injury. Adhesion molecules are normally harbored within the glycocalyx, clothing every healthy vascular endothelium, but shed by ischemia/reperfusion. Our aim was to show whether protection of the glycocalyx with either hydrocortisone or antithrombin can reduce postischemic leukocyte adhesion. Isolated guinea pig hearts, perfused with Krebs-Henseleit buffer, were subjected to 20 min of warm (37 degrees C) no-flow ischemia and consecutive 10 min of reperfusion, either in the absence or presence of hydrocortisone (10 microg/mL) or antithrombin (1 U/mL). An intracoronary bolus of 3 x 10 PMN was applied at the end of reperfusion but without prior contact to the drugs. The sequestration of PMN was calculated from the difference between coronary input and output of cells. Expression of the integrin CD11b on PMN was measured before and after coronary passage. Ischemia/reperfusion induced severe degradation of the glycocalyx (coronary venous syndecan-1 release, 171 +/- 15 ng/g heart vs. basal, 19 +/- 2 ng/g; heparan sulfate, 5.27 +/- 0.28 microg/g vs. basal, 0.26 +/- 0.06 microg/g) and increased PMN adhesion (38.1% +/- 3.5% vs. basal, 11.7% +/- 3.1%). Hydrocortisone and antithrombin both not only reduced glycocalyx shedding (syndecan-1 release, 34 +/- 6 ng/g and 26 +/- 5 ng/g; heparan sulfate, 1.96 +/- 0.24 microg/g and 1.28 +/- 0.2 microg/g, respectively), but also PMN adhesion (17.3% +/- 2.2% and 25.4% +/- 3.3%, respectively) after ischemia/reperfusion. Electron microscopy revealed a mostly intact coronary glycocalyx after pretreatment with either drug. Activation of PMN upon coronary passage was not influenced. Preservation of the glycocalyx mitigates postischemic PMN adhesion. Preconditioning with either hydrocortisone or antithrombin should, thus, alleviate vascular leakage, tissue edema, and inflammation.
机译:多形核中性粒细胞(中性粒细胞)的粘附心脏冠状动脉内皮细胞是一个关键事件缺血/再灌注损伤。通常在glycocalyx庇护,服装每一个健康的血管内皮,但是缺血/再灌注。是否保护glycocalyx要么氢化可的松或抗凝血酶可以降低缺血后白细胞粘附。猪心,灌注Krebs-Henseleit缓冲区,受到20分钟的温暖(37摄氏度)无缺血和连续10分钟再灌注,在没有或存在氢化可的松(10 microg /毫升)或抗凝血酶(1U /毫升)。应用于再灌注但没有结束之前接触到毒品。中性粒细胞计算之间的区别冠状细胞的输入和输出。和之前的整合素对中性粒细胞CD11b测量后冠状通道。诱导glycocalyx严重退化(冠状静脉syndecan-1释放171 + / - 15所示ng / g的心与基底,19 + / - 2 ng / g;硫酸,5.27 + / - 0.28 microg / g和基底,0.26+ / - 0.06 microg / g)和中性粒细胞粘附增加与基底(38.1% + / - 3.5%,11.7% + / - 3.1%)。氢化可的松和抗凝血酶不仅减少glycocalyx脱落(syndecan-1释放,34 + / - 6 ng / g和26 + / - 5纳克/克;1.96 + / - 0.24 microg / g和1.28 + / - 0.2 microg / g,还分别),但中性粒细胞粘附(+ / - 17.3%分别为2.2%和25.4% + / - 3.3%)缺血/再灌注。显示冠状glycocalyx几乎完好无损预处理后用药物。中性粒细胞在冠状通道没有影响。保存glycocalyx减轻缺血后中性粒细胞粘附。氢化可的松或抗凝血酶,因此,减轻血管渗漏,组织水肿,和炎症。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号